Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**BruMeChol** is an Italian oral nutraceutical dietary supplement developed and manufactured by Mivell for use in people with mild hypercholesterolemia. Each capsule contains phytosterols, bergamot fruit extract, olive fruit extract, and vitamin K2; it is supplied as a fixed-dose capsule formulation. Its proposed lipid-management rationale combines reduced intestinal cholesterol absorption by phytosterols with the putative antioxidant, anti-inflammatory, and cholesterol-synthesis-modulating activities of bergamot and olive-derived constituents. In a 12-week randomized, double-blind, placebo-controlled trial in 118 participants with hypercholesterolemia, BruMeChol did not significantly improve total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, or assessed inflammatory biomarkers versus placebo. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9324786/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BruMeChol.